戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 llum assembly or motility, is sufficient for reactogenicity.
2  novel ways to increase dosage and to reduce reactogenicity.
3 man volunteers, suggesting a role for Hap in reactogenicity.
4 nt of V. cholerae culture may play a role in reactogenicity.
5  improve vaccine efficacy but often increase reactogenicity.
6  the safety assessment of local and systemic reactogenicity.
7 ese adjuvants induce some local and systemic reactogenicity.
8 tive RNA vaccine without triggering unwanted reactogenicity.
9 ated, with mild solicited local and systemic reactogenicity.
10 endosomal escape while reducing inflammatory reactogenicity.
11 les can lead to toxicity, and their possible reactogenicity.
12 f seroconversion and is associated with less reactogenicity.
13 associate signatures with immunogenicity and reactogenicity.
14 ants reported predominantly mild-to-moderate reactogenicity.
15 y as well as the influence on any local skin reactogenicity.
16  S-specific T-cell and B-cell responses, and reactogenicity.
17 ain reaction-confirmed influenza and vaccine reactogenicity.
18  304, 6.2-12.6 and 27 [9%] of 293, 6.4-13.1) reactogenicity.
19 -19 vaccine that is immunogenic with minimal reactogenicity.
20 antibodies, S-specific T-cell responses, and reactogenicity.
21       The primary end points were safety and reactogenicity.
22 dent viraemia occurred in concert with early reactogenicity.
23 vants display unacceptable local or systemic reactogenicity.
24 e expected to be devoid of local or systemic reactogenicity.
25  in combination with PF03512676 had enhanced reactogenicity.
26 V2.S vaccine, we assessed immunogenicity and reactogenicity 28 days after a homologous or heterologou
27 bstudy, of whom 80 (89%) were assessable for reactogenicity, 75 (83%) were assessable for evaluation
28                                              Reactogenicity, adverse events, and baseline GMCs were s
29                           Local and systemic reactogenicity, adverse events, binding and neutralising
30 e second dose or a third dose was lower than reactogenicity after a first dose.
31                                              Reactogenicity after a late second dose or a third dose
32                                              Reactogenicity after each dose and safety up to 1 year a
33                        Primary outcomes: (1) reactogenicity after first dose; (2) antibody responses
34 eumatic/inflammatory disorders, but enhanced reactogenicity after live vaccination may occur in those
35                Vaccine virus replication and reactogenicity after monovalent Dengue virus vaccination
36                          Moderate, transient reactogenicity after vaccination occurred more frequentl
37  possible role for hemagglutinin/protease in reactogenicity, although other factors may also contribu
38 le on COVID-19 vaccine booster or third dose reactogenicity among pregnant and lactating individuals.
39  whom 30 were included in immunogenicity and reactogenicity analyses.
40                    The main outcomes for the reactogenicity analysis were symptoms following vaccine
41 as not administered because of the increased reactogenicity and a lack of meaningfully increased immu
42 nd tolerability were evaluated by collecting reactogenicity and adverse event data.
43 re assessed by evaluating local and systemic reactogenicity and adverse events in all participants.
44                                              Reactogenicity and adverse events were monitored through
45                                              Reactogenicity and adverse events were monitored.
46                                      Safety (reactogenicity and adverse events) and efficacy against
47 rimary endpoints included local and systemic reactogenicity and adverse events.
48  the vaccine, assessed as local and systemic reactogenicity and adverse events.
49  vaccines, as assessed by local and systemic reactogenicity and adverse events.
50 painless skin vaccination with reduced local reactogenicity and at least sustained immunogenicity.
51        Safety evaluations included solicited reactogenicity and coagulation parameters.
52 nks between PEG-specific antibodies, vaccine reactogenicity and enhanced clearance of other PEG-conta
53 the 5 x 10(5) dose showed similar safety and reactogenicity and greater immunogenicity when compared
54                                              Reactogenicity and immune responses to cAd3-EBO vaccine
55 ata on COVID-19 messenger RNA (mRNA) vaccine reactogenicity and immunogenicity in pregnancy and for t
56 n-label trial in the United States evaluated reactogenicity and immunogenicity of 2 vaccination regim
57                           Here we report the reactogenicity and immunogenicity of a delayed second do
58           Coprimary outcomes were safety and reactogenicity and immunogenicity of anti-spike IgG meas
59     In a prospective double-blind trial, the reactogenicity and immunogenicity of recombinant baculov
60                              On the basis of reactogenicity and immunogenicity, a dose level of 10 mu
61                              On the basis of reactogenicity and immunogenicity, a dose level of 10 ug
62                            However, systemic reactogenicity and missed activities were significantly
63 2) were associated with more frequent severe reactogenicity and more adverse events than were vaccine
64 Both vaccines were well tolerated, with mild reactogenicity and no serious adverse events related to
65                                      Data on reactogenicity and other adverse events and blood and na
66 atched strains at day 29 and to evaluate the reactogenicity and safety of mRNA-1083.
67                                              Reactogenicity and safety of QIV was consistent with TIV
68                                              Reactogenicity and safety were also assessed.
69 d interim analysis, the primary endpoints of reactogenicity and safety were assessed by blinded study
70 ers against serogroups ACWY, and to evaluate reactogenicity and safety.
71 ratory-confirmed COVID-19, and assessment of reactogenicity and safety.
72                                              Reactogenicity and serious adverse events were monitored
73 Regression models considered the outcomes of reactogenicity and seroconversion, controlling for all s
74 ility of a mouse model for assessing vaccine reactogenicity and strongly indicate that the fever foll
75 nflammatory pulmonary diseases is limited by reactogenicity and suboptimal delivery.
76     Solicited, self-limiting local, systemic reactogenicity and unsolicited adverse events were simil
77  to the associated antigen without increased reactogenicity, and are currently being tested in Phase
78 e report the preliminary findings on safety, reactogenicity, and cellular and humoral immune response
79            Primary endpoints were safety and reactogenicity, and HA and NA antibody responses against
80  Data are limited on the comparative safety, reactogenicity, and health-related quality of life (HRQO
81   Data are needed on the comparative safety, reactogenicity, and health-related quality of life (HRQO
82 mary and secondary objectives of the safety, reactogenicity, and humoral immunogenicity of a quadriva
83  study objectives were assessment of safety, reactogenicity, and humoral immunogenicity of mRNA-1010,
84          The primary end points were safety, reactogenicity, and humoral immunogenicity on trial days
85                      We assessed the safety, reactogenicity, and immunogenicity of a viral vectored c
86              This study assessed the safety, reactogenicity, and immunogenicity of an injectable cell
87                   We aimed to assess safety, reactogenicity, and immunogenicity of ExPEC4V in healthy
88 rimary objectives were to assess the safety, reactogenicity, and immunogenicity of mRNA-1273.214 at 2
89 e 1 dose-ranging study evaluated the safety, reactogenicity, and immunogenicity of mRNA-1345 in adult
90                                  The safety, reactogenicity, and immunogenicity of the CCIV and the e
91        In this trial we compared the safety, reactogenicity, and immunogenicity of the vaccine antige
92  1 of 3 doses and were monitored for safety, reactogenicity, and immunogenicity.
93 inferiority trial evaluating vaccine safety, reactogenicity, and immunogenicity.
94     Present vaccines are immunogenic, of low reactogenicity, and protective, but protection has varie
95 mpare vaccine candidates for immunogenicity, reactogenicity, and response to challenge; investigate t
96 cipants were monitored for vaccine shedding, reactogenicity, and RSV serum antibodies, and followed o
97                     Cellular immunogenicity, reactogenicity, and safety appeared to be comparable bet
98 r-blinded study assessed the immunogenicity, reactogenicity, and safety of an inactivated, split-viri
99 ized study, we evaluated the immunogenicity, reactogenicity, and safety of the AS01E-adjuvanted RSV p
100               HZ/su cellular immunogenicity, reactogenicity, and safety were also assessed.
101                              Immunogenicity, reactogenicity, and safety were assessed.
102 rised additional immunogenicity assessments, reactogenicity, and safety.
103 developed for local reactogenicity, systemic reactogenicity, and specific individual AEs.
104 anti-spike protein response, 7-day solicited reactogenicity, and unsolicited adverse events.
105 ralizing antibodies; cell-mediated immunity; reactogenicity; and safety.
106 d heat-killed Shigella vaccines with minimal reactogenicity are the mutant toxin molecules.
107                       The molecular bases of reactogenicity are unknown, but it has been speculated t
108 duced transgene expression and dose-limiting reactogenicity, as highlighted by recent clinical trials
109            Primary safety endpoints included reactogenicity assessed for the first 7 days and all adv
110 eatment; medical staff performing safety and reactogenicity assessments or blood draws for immunogeni
111                                         High reactogenicity associated with an increased dose of vCP1
112 antigens by developing biomarkers of vaccine reactogenicity associated with potential adverse events.
113  well tolerated but was associated with more reactogenicity at the highest dose.
114 d cytokine recall responses but reduced skin reactogenicity at the injection site.
115                              It displayed no reactogenicity at the site of injection, no tissue disea
116 to provide tools to identify inflammatory or reactogenicity biomarkers.
117 olysin and MARTX toxin contribute to vaccine reactogenicity but that the genes for these toxins can b
118           We examined ways of reducing their reactogenicity by modifying lipid A, the endotoxic part
119                                              Reactogenicity cannot be used to predict immunity after
120 nt, causing increased serosal hemorrhage and reactogenicity compared to its parent.
121 otein expression without causing significant reactogenicity compared to LNPs containing ALC-0315.
122 3, but not NVX, increased transient systemic reactogenicity compared with homologous schedules.
123 as a heterologous booster, demonstrates less reactogenicity compared with mRNA vaccines, which, if co
124 igher incidence and an increased severity of reactogenicity compared with the Novavax protein-based C
125                     We solicited symptoms of reactogenicity daily for 7 days after each vaccination a
126 , children received 1 dose of 2010/2011 TIV, reactogenicity data were collected for 7 days, and anoth
127 -1 was at high dose and all others were low; reactogenicity decreased with the incorporation of other
128                         While reducing local reactogenicity, EPD of OVA/LPS/CpG and BCG vaccine gener
129            Primary safety endpoints included reactogenicity events and adverse events (AEs) through 7
130            Secondary outcomes were solicited reactogenicity events and unsolicited adverse events (AE
131                           Local and systemic reactogenicity events from the third dose were generally
132                              The most common reactogenicity events were headache (n = 4,923) and body
133                                  Most common reactogenicity events were injection site tenderness and
134                                         Most reactogenicity events were mild or moderate in severity
135                                         Most reactogenicity events were mild/moderate; severe events
136               Preliminary local and systemic reactogenicity events were more common in the vaccine gr
137                                     BNT162b2 reactogenicity events were mostly mild to moderate, with
138                             In older adults, reactogenicity events were predominantly mild or moderat
139            Primary safety endpoints included reactogenicity events within 7 days and adverse events (
140 A/H1N1 strains, but was associated with more reactogenicity events.
141 nically observed Trumenba local and systemic reactogenicity fell on the 26th and 93rd percentiles of
142 CFU, self-limited (<48-h duration) objective reactogenicity (fever, diarrhea, or dysentery) developed
143 titres and a gene signatures associated with reactogenicity (Geneva cohort) was identified correlatin
144                                      Vaccine reactogenicity has complicated the development of safe a
145                                              Reactogenicity hinders worldwide implementation of the o
146  In a blinded, placebo-controlled study, the reactogenicity, immunogenicity, and clinical efficacy of
147 etry, contributing directly to immunological reactogenicity in bone marrow-derived dendritic cells.
148 though TIV was well tolerated in all groups, reactogenicity in children <5 years old was slightly gre
149 racts of mice and ferrets, and have very low reactogenicity in ferrets.
150 nt of safety, assessed as local and systemic reactogenicity in the 7 days after each vaccination and
151 irus, a vaccine candidate that retained mild reactogenicity in the upper respiratory tracts of 1-mont
152                                        Local reactogenicity in the vaccine groups was common, but the
153 genes from Vibrio cholerae induce a residual reactogenicity in up to 10% of vaccinees.
154 rimary series and yearly boosters and causes reactogenicity in up to 30% of vaccine recipients.
155 n attenuated vaccine candidate with residual reactogenicity in very young infants, namely, cpts248/40
156 ellular responses (i.e., protein expression, reactogenicity) in multiple cell models.
157 cine providing durable immunity with minimal reactogenicity is needed.
158 unity without incurring any significant skin reactogenicity is urgently needed for cutaneous vaccinat
159 h dose immunization results in minimal local reactogenicity, is well-tolerated, and does not elevate
160                    The primary outcomes were reactogenicity; laboratory values (serum chemistry and h
161 s reported fever; only 1 reported any severe reactogenicity (local pain/soreness, chills, arthralgia,
162    CoronaVac vaccine was associated with low reactogenicity, low immunogenicity but reduced incidence
163 s are often associated with toxic effect and reactogenicity, necessitating expanding the repertoire o
164                                              Reactogenicity occurred in 8 of 23 recipients of CVD 120
165                                              Reactogenicity occurred less frequently and was of lower
166                                  The highest reactogenicity occurred when DENV-1 was at high dose and
167                             Similar clinical reactogenicity occurred with both vaccines.
168      Using this mouse model, we explored the reactogenicity of 4CMenB components by measuring changes
169           We compared the immunogenicity and reactogenicity of a fractional dose of IPV (one fifth of
170    An open study assessed immunogenicity and reactogenicity of a heterologous booster dose of A/turke
171                       The immunogenicity and reactogenicity of a homologous or heterologous booster i
172 s in Geneva to assess the immunogenicity and reactogenicity of a novel recombinant aP (r-aP) vaccine
173  vaccine and assessed the immunogenicity and reactogenicity of a subsequent dose of trivalent influen
174                    Despite a higher observed reactogenicity of AS01-containing vaccines, no safety co
175 r biology, clinical spectrum of illness, and reactogenicity of candidate live dengue virus vaccines o
176           We compared the immunogenicity and reactogenicity of Cervarix or Gardasil human papillomavi
177 COVID-19 outcomes and the immunogenicity and reactogenicity of COVID-19 mRNA vaccination among patien
178  the relationship between immunogenicity and reactogenicity of COVID-19 vaccines.
179   The primary end points were the safety and reactogenicity of each dose schedule.
180 protease that modulates the pathogenesis and reactogenicity of epidemic V. cholerae.
181 that a trxA mutation might be used to reduce reactogenicity of live attenuated vaccine strains.
182 enterotoxicity in rabbit ileal loops and the reactogenicity of live cholera vaccine candidates.
183 have mucinase activity and contribute to the reactogenicity of live vaccine candidates, but its role
184                                   Safety and reactogenicity of MenACWY were also assessed.
185 to-head comparison of the immunogenicity and reactogenicity of PCV10 and PCV13.
186                       The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with c
187 r clinical development can be limited by the reactogenicity of some of the most potent preclinical ad
188                               The safety and reactogenicity of the 2 vaccines were assessed on the ba
189  the study were the evaluation of safety and reactogenicity of the adjuvanted recombinant zoster vacc
190 result demonstrated that IL-1 contributed to reactogenicity of the rVSV, but was dispensable for indu
191  assessed using logistic regression, and the reactogenicity of the vaccines was compared.
192 activity in vitro did not correlate with the reactogenicity of V. cholerae vaccine candidates.
193  study was to compare the immunogenicity and reactogenicity of vaccines delivered in either consisten
194 tro has been suggested to correlate with the reactogenicity of Vibrio cholerae vaccine candidates.
195 ic drop in incidence, concerns regarding the reactogenicity of wP vaccines led to the development of
196 ection) and tolerability (local and systemic reactogenicity) of the vaccine, and the secondary outcom
197 s, and solicited injection site and systemic reactogenicity on the day of study product administratio
198  on Phase 1/2 trials, evaluating the safety, reactogenicity, optimal doses, routes of administration,
199 participants with mild, moderate, and severe reactogenicity or adverse events, graded as per the Divi
200  No statistically significant differences in reactogenicity or immunogenicity were detected between s
201                        The primary composite reactogenicity outcome was the proportion of participant
202                                              Reactogenicity outcomes were proportions of injection si
203                           Primary safety and reactogenicity outcomes were unsolicited adverse events
204 fety data were collected including immediate reactogenicity, post-dosing toxicology ascertained 24 h
205 ework for the further development of vaccine reactogenicity predictive models.
206 file, with mainly transient mild-to-moderate reactogenicity (predominantly injection-site pain [in 79
207 quential administration and had a safety and reactogenicity profile consistent with both vaccines adm
208 ar immune responses were correlated with the reactogenicity profile of subjects and did not differ be
209                                          The reactogenicity profile of TDV was acceptable, and simila
210 e regimens were well tolerated, with similar reactogenicity profiles among them.
211                   H56:IC31 showed acceptable reactogenicity profiles irrespective of dose, number of
212 y relevant difference between the safety and reactogenicity profiles of the 2 vaccines.
213 ntibody titres at day 28, local and systemic reactogenicity profiles, adverse events, and serious adv
214 accines had clinically acceptable safety and reactogenicity profiles.
215 ine formulations and the placebo had similar reactogenicity profiles.
216  of gE while retaining acceptable safety and reactogenicity profiles.
217 beit analysis by age indicated greater local reactogenicity rates for adolescents (46% for TAK-003 an
218            Treatment was well tolerated with reactogenicity rates similar to those seen in non-pregna
219                                              Reactogenicity rates were similar in LAIV and placebo re
220                At 3 x 10(5) pfu, early-onset reactogenicity remained frequent (45 [88%] of 51 compare
221 nses; however, balancing immunogenicity with reactogenicity remains problematic.
222 stinct physiological (temperature/heart rate/reactogenicity) response-patterns not seen with non-adju
223 1]) and were monitored for vaccine shedding, reactogenicity, RSV-antibody responses and RSV-associate
224                                              Reactogenicity, safety, and immunogenicity measured by h
225                                              Reactogenicity/safety of the revaccination dose were sim
226 RSV administered to 6- to 7-month-olds had a reactogenicity/safety profile like other childhood vacci
227 nted FLU-aQIV and RSVPreF3 OA had acceptable reactogenicity/safety profiles when co-administered in >
228                                      A novel reactogenicity scoring framework accounting for the freq
229                     AEs were mostly expected reactogenicity signs and symptoms.
230 as common, but the frequency and severity of reactogenicity signs or symptoms did not differ between
231                                              Reactogenicity solicited for 7 days, other safety events
232 be further enrolled in an immunogenicity and reactogenicity sub-study to evaluate the safety profile
233  Children enrolled in the immunogenicity and reactogenicity sub-study will have blood drawn before va
234        The most frequently reported systemic reactogenicity symptoms in the active vaccine groups wer
235   Predictive models were developed for local reactogenicity, systemic reactogenicity, and specific in
236        The primary endpoints were safety and reactogenicity (take rate) of CCSV.
237 ent the results of secondary immunogenicity, reactogenicity, tetanus toxoid IgE-mediated immune respo
238 t immunogenic and was associated with higher reactogenicity than the BNT162b2 and Ad26.COV2.S booster
239 -Hist did not exhibit the immunogenicity and reactogenicity that can limit repeated LNP dosing.
240 fy putative biomarkers of early inflammation/reactogenicity that could guide the design of subsequent
241  separated by 2-6 months, local and systemic reactogenicity that is significantly greater than observ
242               Among participants with severe reactogenicity, the mean (SD) EQ-5D-5L Index score decre
243                                              Reactogenicity, the occurrence of adverse local/systemic
244 participants had injection site and systemic reactogenicity, these symptoms were mostly mild to moder
245 and immunogenic cell death and (3) favouring reactogenicity through the modulation of factors that co
246 p short-term immunity and may have increased reactogenicity to coronavirus disease 2019 (COVID-19) va
247      Here, we used an infant rabbit model of reactogenicity to determine what V. cholerae factors tri
248 valuation included analyses of postinjection reactogenicity, unsolicited adverse events (AEs), seriou
249            An accurate prediction of vaccine reactogenicity using in vitro assays and computational m
250                                     Systemic reactogenicity varied by vaccine and correlated with imm
251                                              Reactogenicity was absent or mild in the majority of par
252                                 Immunization reactogenicity was also reviewed.
253                                              Reactogenicity was assessed for 7 days after vaccination
254         In this interim analysis, safety and reactogenicity was assessed in all individuals who recei
255                                              Reactogenicity was assessed up to 7 days after vaccinati
256                                     Clinical reactogenicity was assessed, and state-of-the-art immuno
257                                              Reactogenicity was associated with adjuvant but not with
258 Mild to moderate injection site and systemic reactogenicity was common but brief.
259                                              Reactogenicity was comparable between groups.
260 stration of mRNA COVID-19 and IIV4 vaccines, reactogenicity was comparable in both groups.
261                 Mild-to-moderate early-onset reactogenicity was frequent but transient (median, 1 day
262                                              Reactogenicity was generally mild and transient.
263                                              Reactogenicity was generally mild or moderate and resolv
264 mild to moderate in severity; injection site reactogenicity was greater in vaccination groups receivi
265                                              Reactogenicity was higher after the booster injection bu
266                                              Reactogenicity was higher with Ad26.COV2.S than with pla
267                                              Reactogenicity was largely mild to moderate and transien
268                                              Reactogenicity was lower after the second dose.
269                                     Systemic reactogenicity was mild in all groups.
270              All reported local and systemic reactogenicity was mild to moderate in severity.
271                                              Reactogenicity was mild, transient, and most commonly re
272                                              Reactogenicity was minimal with doses of 5 x 10(10) vp o
273 containing 15, 45, or 135 microg of each HA, reactogenicity was minor.
274                                              Reactogenicity was monitored to day 7 and unsolicited ad
275                              Transient local reactogenicity was more frequently seen at the higher do
276                                              Reactogenicity was mostly mild to moderate and transient
277                                        Local reactogenicity was observed after administration of N6LS
278                                 Self-limited reactogenicity was observed after the initial immunizati
279                                 Self-limited reactogenicity was observed after the initial immunizati
280                             Mild to moderate reactogenicity was observed after vaccination, with symp
281                   Primarily mild or moderate reactogenicity was observed in both vaccine groups but w
282                                              Reactogenicity was predominantly mild to moderate in sev
283                        More pronounced local reactogenicity was seen with the intradermal and subcuta
284                  BCG was well tolerated, and reactogenicity was similar between groups, regardless of
285                                              Reactogenicity was similar to that of mRNA-1273 vaccines
286                                              Reactogenicity was similar to that reported for the prim
287 lant recipients undergoing mRNA vaccination, reactogenicity was similar to that reported in the origi
288                           Local and systemic reactogenicity was transient and self-limiting.
289 ticipants reported solicited and unsolicited reactogenicity; we measured IgG binding, neutralizing an
290 ticipants reported solicited and unsolicited reactogenicity; we measured immunoglobulin G binding, ne
291                           Local and systemic reactogenicities were consistent with intramuscular need
292                  Rates of local and systemic reactogenicities were higher with 3A-HBV compared with 1
293 odified intention-to-treat basis; safety and reactogenicity were assessed in the intention-to-treat p
294                        Solicited symptoms of reactogenicity were assessed, and all safety assessments
295  RSV serum antibodies, vaccine shedding, and reactogenicity were assessed.
296 ccurrence and severity of local and systemic reactogenicity were similar across active groups.
297                                   Safety and reactogenicity were similar with the two booster vaccine
298 ustly activate newborn DCs but can result in reactogenicity when delivered in soluble form.
299 nistration of rBCG was associated with local reactogenicity, whereas intravenous and intradermal admi
300 (saRNA-5mC) has demonstrated reduced vaccine reactogenicity while maintaining robust humoral response

 
Page Top